FDA Approves Tecvayli Combo, Accepts Iberdomide NDA for Relapsed/Refractory Myeloma
The FDA approved Tecvayli plus Darzalex Faspro for relapsed or refractory multiple myeloma after at least one prior therapy, and accepted a new drug application for iberdomide plus daratumumab and dexamethasone with a PDUFA date of August 17, 2026.